Founded in 1997, Pharmasyntez is now Russia's largest manufacturer of anti-TB drugs. Since 2011 Parmasyntez is among the top ten pharmaceutical companies in Russia in terms of production (as reported by Remedium magazine). Pharmasyntez increases its sales turnover every year. Our company has the most complete nomenclature of anti-TB drugs on the Russian market. At three manufacturing sites there are available about 50 items of drugs in different dosages: capsules, tablets, granules, infusion solutions. By 2013 we are planning to start manufacturing ARV drugs, anticancer drugs, expand the range of antibiotics. The product range will increase to at least 70 items introducing new dosage forms: vials, sterile dry powders and solutions for injection. Over the years Pharmasyntez has gained enormous experience in building high-tech pharmaceutical plants – there were commissioned two pharmaceutical plants in Irkutsk (solid drugs production) and one plant in Primorsky Krai (infusion solutions production) To implement our plans several investment projects have been already started. The investments will amount to about 3,1 billion RUR (approximately 100 million USD). Together with the Federal State Institution Saint-Petersburg Research Institute for Phthisiopneumology of the Federal Agency of High-tech Medical Car" the company is accomplishing research of the new innovative drug of Perhlozone,synthesized at A.E. Favorskiy Irkutsk Research Institute of Chemistry. This drug is an important step forward in tuberculosis treatment. Pharmasyntez invites foreign and Russian companies to work together for introduction innovative drugs in Russia. Developed infrastructure and professionalism of our employees allow us to be confident in the productivity of our cooperation.